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Abstract
Objective: We examined whether a panel of SNPs, systematically selected from genome-wide association studies (GWAS),
could improve risk prediction of coronary heart disease (CHD), over-and-above conventional risk factors. These SNPs have
already demonstrated reproducible associations with CHD; here we examined their use in long-term risk prediction.
Study Design and Setting: SNPs identified from meta-analyses of GWAS of CHD were tested in 840 men and women aged
55–75 from the Edinburgh Artery Study, a prospective, population-based study with 15 years of follow-up. Cox proportional
hazards models were used to evaluate the addition of SNPs to conventional risk factors in prediction of CHD risk. CHD was
classified as myocardial infarction (MI), coronary intervention (angioplasty, or coronary artery bypass surgery), angina and/or
unspecified ischaemic heart disease as a cause of death; additional analyses were limited to MI or coronary intervention.
Model performance was assessed by changes in discrimination and net reclassification improvement (NRI).
Results: There were significant improvements with addition of 27 SNPs to conventional risk factors for prediction of CHD
(NRI of 54%, P,0.001; C-index 0.671 to 0.740, P= 0.001), as well as MI or coronary intervention, (NRI of 44%, P,0.001; C-
index 0.717 to 0.750, P= 0.256). ROC curves showed that addition of SNPs better improved discrimination when the
sensitivity of conventional risk factors was low for prediction of MI or coronary intervention.
Conclusion: There was significant improvement in risk prediction of CHD over 15 years when SNPs identified from GWAS
were added to conventional risk factors. This effect may be particularly useful for identifying individuals with a low
prognostic index who are in fact at increased risk of disease than indicated by conventional risk factors alone.
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Introduction
There has been much discussion of personalised medicine
and the use of genetic risk scores for identifying people at
increased risk for chronic diseases including coronary heart
disease (CHD). The expectation is that such individuals might
benefit from targeted interventions, thereby reducing their risk
of developing disease. The Framingham risk score [1] is the
most commonly used method of CHD risk prediction, and has
been widely assessed for validity. However, the accuracy of this
score differs between populations, commonly over-estimating
risk in European countries [2], and overall accuracy is generally
low for individuals not at the extremes of risk distributions.
Alternative risk prediction models have been developed which
incorporate a range of additional risk factors, such as bio-
markers [3], socio-economic indicator, or family history [4], but
these still have limited predictive power.
Family history is predictive of CHD after adjusting for other
conventional risk factors [5,6], and CHD is estimated to be
approximately 40–50% heritable [7,8]. Despite this, genetic in-
formation has so far generally not resulted in appreciable
improvements in prediction over non-genetic risk factors, (apart
frommonogenic disease). This is likely due in part to the small effects
exerted by individual single nucleotide polymorphisms (SNPs)
relative to established risk factors; but the selection of SNPs for
evaluation, and methods of inclusion in a predictive model, are also
likely contributors. Previous genetic risk prediction models have
often relied on candidate SNPs that have a known biological role in,
or association with, CHD or atherosclerosis [9]. The publication of
genome-wide association studies (GWAS) has provided another
method for identification of SNPs, independent of known biological
function, but based on statistical evidence of association. Models
have often used genetic risk scores, basically a sum of the number of
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risk alleles, which do not take into account the individual effect sizes
and assume independence of these alleles.
The primary aim of this analysis was to determine whether
a systematically selected panel of SNPs, already found individually
to be reproducibly associated with CHD through GWAS, could
improve prediction of CHD over and above well established
conventional risk factors, thereby contributing additional clinical
utility. Since the majority of coronary events occur in individuals
with Framingham based risk scores of less than 20% [10], the
inclusion of genetic information has the potential to create a more
personalised and accurate risk evaluation.
Methods
Study Population
Details of the Edinburgh Artery Study (EAS), have been
published previously [11,12]. In brief, the EAS enrolled 1592 men
(809) and women (783) aged 54–75 years living in Edinburgh,
Scotland. Recruitment used an age-stratified random sample from
ten general practices, resulting in a geographical and socio-
economic representation of the population of Edinburgh. Clinical
examinations were held during 1987/8, and DNA samples were
collected at a five year follow-up examination (attended by 1165
(73%) subjects). At time of genotyping for the current study (2009),
DNA was available for 856 subjects, of which 840 were
successfully genotyped (409 men, 431 women). Reasons for not
having a DNA sample included refusal to provide a blood sample
or allow genotyping at the 5-year examination, or insufficient
sample remaining. Baseline characteristics of the full EAS
population and the population used for the current analysis were
very similar (Table 1).
Data collection for identification and validation of coronary
events at baseline and throughout follow-up included the WHO
chest pain questionnaire, ECG (coded using Minnesota Classifica-
tion Code), self-reported doctor diagnosis of disease, record linkage
to hospital discharge data and death certificates, and scrutiny of
general practitioner records [12]. Conventional risk factors mea-
sured at baseline included lipids and blood pressure. Complete
follow-up was available until June 2003, a mean follow-up of 15
years.
The classification of CHD used in the current analyses was
based on validated events and comprised of fatal or non-fatal
myocardial infarction (MI), angioplasty, coronary artery bypass
surgery, angina and/or unspecified ischaemic heart disease as
a cause of death. To reduce the potential for mis-classification,
further analyses were restricted to fatal or non-fatal MI or
coronary intervention (angioplasty or coronary artery bypass
surgery). Family history was also collected at baseline, but was
limited to unconfirmed self-reports of MI or angina in a parent.
Ethical Approvals
Ethical approval for the EAS was granted by the Lothian
Health Board Medical Research Ethics Committee. Written
informed consent was obtained from all participants.
SNP Identification
Selection of SNPs used recent large scale meta-analyses of
GWAS of CHD to identify SNPs that have demonstrated
reproducible associations with CHD [13,14]. This provided 36
SNPs, of which six were not available on Metabochip
(rs10953541, rs1412444, rs17609940, rs216172, rs46522,
rs964184) and no proxy was available; rs4977574 was replaced
with rs133049 (r2 = 0.97, D’ = 1.0). Three SNPs were removed
because they were in LD (r2.0.85) with other included SNPs
(rs646776, rs1199338, rs12526453). Details of SNPs used in
prediction models are presented in Table 2 (detailed in Table S1).
Additional SNPs for use in a secondary, exploratory analysis
were selected based on nominal significance (P,161025) in
GWAS of CVD, significant associations with lipids in GWAS,
and/or biological plausibility. This provided an additional 44
SNPs (detailed in Table S2) that were available and successfully
genotyped in the study population, resulting in a total set of 74
Table 1. Comparison of baseline characteristics of the EAS population used in genetic risk prediction models and full study
population.
Study population (1592) Genotyped population (840)
Mean (95%CI) Mean (95%CI)
Age at baseline 64.9 (64.6,65.1) 64.4 (64.0,64.8)
Body Mass Index 25.6 (25.4,25.8) 25.5 (25.3,25.8)
Systolic Blood Pressure 144 (143,146) 143 (142,145)
Diastolic Blood Pressure 77 (77,78) 77 (77,78)
Total Cholesterol 7.03 (6.97,7.10) 7.08 (6.99,7.02)
HDL Cholesterol 1.44 (1.42,1.46) 1.45 (1.42,1.50)
LDL Cholesterol 5.28 (5.22,5.34) 5.33 (5.25,5.40)
log(Triglycerides) 0.15 (0.14,0.16) 0.14 (0.13,0.20)
n (%) n (%)
Sex Male 809 (51) 409 (49)
Diabetes 288 (18.1) 136 (16.2)
Family History in parent 576 (36.2) 257 (38.0)
Current Smoker 404 (25.4) 182 (21.7)
Previous Smoker 582 (36.6) 315 (37.5)
Never Smoked 561 (35.2) 328 (39.0)
doi:10.1371/journal.pone.0057310.t001
Genetic Markers in Prediction of CHD Risk
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SNPs for use in secondary analysis. This was a more subjectively
selected and therefore potentially biased set of SNPs.
Genotyping
Genotyping used the Illumina MetaboChip, from which the
chosen SNPs were extracted. Quality control was carried out on
the full MetaboChip results, 16 samples with call rates below 75%
were excluded. Table S1 reports: call rates, mean genotypic call
rate of 97.7% (range 85.5–99.5); Hardy Weinberg Equilibrium
(HWE), one SNPs showed deviation from HWE (rs4773144); and
minor allele frequencies (MAF), range 3–49%.
Statistical Analysis
Statistical analysis used R version 2.14.0 [15], all p-values were
two-sided. Prediction of coronary risk used multivariate adjusted
Cox proportional hazards in the survival library [16], the
assumption of proportional hazards was satisfied for all models.
Conventional risk factors were based on the Framingham model
[1], and included: sex, baseline age, systolic blood pressure,
smoking (Yes/No), diabetes and/or glucose intolerance (Yes/No),
and total cholesterol/HDL cholesterol. SNPs were added as
covariates to the conventional risk factors, assuming an additive
model. This was thought preferable to creation of a single genetic
risk score as it allows more influential SNPs to exert more of an
effect on the model, whereas a composite risk score assumes all
SNPs have the same effect size. The derived ß coefficients were
used to calculate prognostic indices, thereby creating weighted
prediction models. Prognostic indices were converted to predicted
probabilities as 12S0(t)
exp(PI) [1].
Model performance was evaluated by C-indices, net reclassifi-
cation indices (NRI), integrated discrimination improvement (IDI),
and plotted ROC curves. ROC curves were plotted using the
ROCR library [17], C-indices, NRI, and IDI used the Hmisc library
[18]. The C-index used in survival analysis is analogous to area
under the ROC curve used in logistic regression, simply it is
a measure of the concordance in predicted and observed survival
times between subjects [19]. NRI was based on event specific
reclassification and used continuous measures rather than
categories, which increases statistical power. NRI can be used to
compare the clinical impact of different models, simply, it is
a comparison of the proportion of subjects with disease who have
appropriately increased risk scores with the new model, and the
proportion of subjects without disease who have appropriately
decreased risk scores with the new model [20]. IDI represents
desired improvements in average sensitivity corrected for undesir-
able increases in 1-specificity, it therefore compared whether the
new models improved sensitivity without affecting specificity, as
described in Pencina et al. (2008). ROC curves are plots of 1-
Table 2. SNPs identified from meta-analysis of GWAS of CHD used in risk prediction models.
SNP Chr Position (b37) Gene(s) Alleles Minor allele MAF
rs11206510 1 55,268,627 PCSK9 C/T C 0.16
rs17114036 1 56,735,409 PPAP2B A/G G 0.11
rs599839 1 109,623,689 SORT1 A/G G 0.28
rs17011666 1 220,865,588 MIA3 A/G G 0.17
rs17465637 1 220,890,152 MIA3 A/C A 0.27
rs6725887 2 203,454,130 WDR12 C/T C 0.16
rs2306374 3 139,602,642 MRAS C/T C 0.18
rs1332844 6 12,996,990 PHACTR1 C/T C 0.39
rs12190287 6 134,256,218 TCF21 C/G G 0.40
rs3798220 6 160,881,127 LPA C/T C 0.00
rs11556924 7 129,450,732 ZC3HC1 C/T T 0.39
rs1333049 9 22,115,503 CDKN2A, C/G C 0.46
rs579459 9 135,143,989 ABO C/T C 0.20
rs2505083 10 30,375,128 KIAA1462 C/T C 0.43
rs1746048 10 44,095,830 CXCL12 C/T T 0.15
rs12413409 10 104,709,086 CYP17A1, CNNM2, NT5C2 A/G A 0.08
rs974819 11 103,165,777 PDGFD C/T T 0.22
rs3184504 12 110,368,991 SH2B3 C/T T 0.45
rs4773144 13 109,758,713 COL4A1, COL4A2 A/G G 0.42
rs2895811 14 99,203,695 HHIPL1 C/T C 0.42
rs3825807 15 76,876,166 ADAMTS7 A/G G 0.45
rs4380028 15 76,898,148 ADAMTS7-MORF4L1 C/T T 0.41
rs12936587 17 17,484,447 RASD1, SMCR3, PEMT A/G G 0.47
rs1122608 19 11,024,601 LDLR G/T T 0.26
rs2228671 19 11,071,912 LDLR C/T T 0.11
rs9982601 21 34,520,998 MRPS6 C/T T 0.21
rs7278204 21 34,543,235 SLC5A3-MRPS6-KCNE2 A/G G 0.17
doi:10.1371/journal.pone.0057310.t002
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specificity vs sensitivity, allowing visualisation of changes in
discrimination over different sensitivities.
All analyses used first incident events only, subjects with
a diagnosis of prevalent CHD at baseline were excluded, as
appropriate. Time to event was determined individually for both
CHD and fatal or non-fatal MI or coronary intervention, based on
appropriate diagnostic criteria. Since models based on different
subjects could differ, risk prediction models that were compared
contained identical population groups. Power was calculated using
the gap library [21]. Though underpowered to detect significant
associations for individual SNPs, it was hypothesised that a set of
SNPs with high prior probability could jointly have a sufficiently
large effect size. There was 80% power to detect an effect size of
1.5 with a minor allele frequency (MAF) of 30% in a multiplicative
model, at 5% significance with a disease prevalence of 20%.
An exploratory method of selecting SNPs used regression trees
in the rpart library [22]. To identify SNPs that were informative
after conventional risk factors, the residuals of a model containing
conventional risk factors were used as the dependent variable. This
analysis included the full collection of 74 SNPs as potential
covariates. Tree development used the Gini Index as the splitting
rule, SNPs were treated as ordinal, and splitting was only
considered as dominant or recessive models. Regression trees
sequentially selected SNPs that best partitioned subjects into the
appropriate group [23]; the sets of SNPs that were identified by
the regression trees were then used to develop prediction models.
Results
Risk Prediction Using SNPs with Confirmed Associations
with CHD
27 SNPs identified in meta-analysis of GWAS of CHD were
successfully genotyped in the EAS population (Table 2), and results
of prediction models are summarised in Table 3 (hazard ratios given
in Tables S3 and S4). Addition of the 27 SNPs to conventional risk
factors in prediction of CHD increased the C-index from 0.671 to
0.740 (P=0.001) and NRI was 54% (95%CI 35–74; P,0.001).
When restricted to fatal or non-fatalMI or coronary intervention the
C-index increased from 0.717 to 0.750 (P=0.256), and NRI was
44% (95%CI 20–67; P,0.001). The results were almost identical
when family history of CHD was also included in the models.
Plotted ROC curves (Figure 1) showed that addition of SNPs
improved prediction over much of the curve for CHD, however
for fatal or non-fatal MI or coronary intervention the models
performed differently at different sensitivities when SNPs were
added; here the addition of SNPs better improved discrimination
when the sensitivity of conventional risk factors was lower,
translating to improved identification of an individual with a low
prognostic index in fact at increased risk of an event. This was
mirrored in density plots, in which a second distribution of higher
risk scores for subjects with events emerged upon addition of SNPs
(Figure S1). Addition of SNPs to conventional risk factors moved
10 subjects to predicted risk $20%, and increased the OR of
having any CHD given a $20% predicted risk increased from
3.86 (95%CI 2.52,5.93) to 5.42 (95%CI 3.54,8.38). When
restricted to fatal or non-fatal MI or coronary intervention, 16
subjects moved to predicted risk $20%., and the odds ratio of
having an event given a $20% predicted risk increased from 4.42
(95%CI 1.78,10.46) to 12.18 (95%CI 6.30,24.03).Reclassification
tables are presented in Table S5.
Risk Prediction Using SNPs Identified from Regression
Trees
The use of regression trees to identify SNPs that explained the
remaining variance after consideration of conventional risk factors
was a secondary, exploratory approach to developing prediction
models. Of the potential 74 SNPs, seven SNPs were found to
explain some of the remaining risk of CHD: rs1122608
(SMARCA1), rs3798220 (LPA), rs780094 (GCKR), rs1332844
(PHACTR1), rs11668477 (LDLR), rs3184504 (SH2B3), rs2505083
(KIAA1462). When done for fatal or non-fatal MI or coronary
intervention, the list of nine predictive SNPs differed: rs780094
(GCKR), rs17011666 (MIA3), rs11556924 (ZC3HC1), rs3798220
(LPA), rs4939883 (LIPG), rs12413409 (CNNM2), rs17145738
(TBL2/MLXIPL), rs174570 (FADS1/2), rs173539 (CETP). Re-
gression trees are shown in Figure S2, model results in Table 3,
and ROC curves in Figure S3. Addition of regression tree SNPs to
conventional risk factors increased the C-index for prediction of
CHD from 0.668 to 0.709, (P=0.027), had a NRI of 42% (95%CI
25,58; P,0.001), and moved six subjects with CHD to predicted
risk $20%. The SNPs predictive of fatal or non-fatal MI or
coronary intervention increased the C-index from 0.694 to 0.718
(P=0.463), had a NRI of 43% (95%CI 22,63; P,0.001), and
moved 15 subjects to predicted risk $20%.
Discussion
In this prospective, population-based cohort of men and women
from Edinburgh, Scotland, a systematically-selected set of SNPs
improved prediction of CHD over 15 years, over-and-above
conventional risk factors. A total of 27 SNPs that were significantly
associated with CHD, when added to the Framingham-based
conventional risk factors of age, sex, SBP, total cholesterol/HDL
cholesterol, diabetes and/or glucose intolerance, and smoking,
improved prediction as indicated by significant improvements in
NRI and C-indices. NRI were used to evaluate the clinical impact
of addition of SNPs. Given that an estimated 15–20% of MI occur
in individuals considered as lower risk based on conventional risk
factors [24], the ability of this genetic model to identify such
subjects and increase their predicted risk indicates potential
clinical utility. The highest risk category of at least 20% CHD
risk was of interest as individuals in this category are often
considered suitable for clinical intervention, and the risk of mis-
classification is decreased [25]. The appropriate reclassification of
subjects to $20% predicted risk on addition of SNPs to
conventional risk factors suggests that such a model could affect
treatment decisions for a number of individuals.
Regression trees were used to evaluate whether a smaller
collection of SNPs was sufficient to improve prediction, to account
for the possibility that not all SNPs contribute to prediction. This
allowed for selection of additional SNPs as it was not expected that
GWAS would have sufficient power to identify all associated and/
or predictive SNPs. Though regression trees are prone to over
fitting, they were an exploratory method to limit the number of
SNPs included in the models. They also provided branching
patterns that may show that an effect at one SNP may only occur
in the presence of another SNP. This would indicate that only
SNPs with independent effects should be included, in order to get
more accurate population based risk associated with the SNP.
Previous studies that added candidate SNPs to conventional risk
factors, using either genetic risk scores (a count of the number or
risk alleles) or weighting of SNPs, have generally not significantly
improved model discrimination as measured by C-index. They
have however indicated through NRI [26] and/or increased
hazard ratios that SNPs could improve risk prediction
Genetic Markers in Prediction of CHD Risk
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[27,28,29,30,31]; with significant associations reported between
incident CHD and genetic risk scores [26,27,28]. Humphries et al.
(2007) [32] found a significant improvement in C-index in the
Northwick Park Heart Study II (P,0.001), which was further
improved after inclusion of an interaction with smoking (P=0.01).
More recently there have been other studies that used GWAS-
identified SNPs in prospective cohorts; these contained many but
not all of the GWAS SNPs used in the present analyses. Paynter et al.
(2010) [6] assessed the predictive ability of adding genetic risk scores
to conventional risk factors for prediction of any CVD (MI, stroke,
arterial revascularization, and cardiovascular death) in a large
Table 3. Incidence, Discrimination, and Calibration Estimates of Models Using Conventional Risk Factors* and GWAS or Regression
Tree SNPs in the EAS.
Concordance R2 C-index NRI (95% CI)
NRI event/
nonevent IDI (95% CI)
SNPs identified through GWAS of CHD
CHD (n=508, 131 incident events)
Conventional risk factors 0.658 0.081 0.671
Conventional risk factors & SNPs 0.712 0.137 0.740 54.4 (34.5,74.3) 17.6/36.9 0.04 (0.02,0.06)
Conventional risk factors & Family history 0.658 0.082 0.671
Conventional risk factors, Family history & SNPs 0.712 0.138 0.741 54.4 (34.5,74.3) 17.6/36.9 0.04 (0.02,0.06)
Fatal or non-fatal MI or coronary intervention (n =590, 81 incident events)
Conventional risk factors 0.701 0.062 0.717
Conventional risk factors & SNPs 0.731 0.106 0.750 43.5 (20.1,67.0) 11.1/32.4 0.05 (0.02,0.08)
Conventional risk factors & Family history 0.702 0.063 0.718
Conventional risk factors, Family history & SNPs 0.734 0.107 0.753 42.7 (19.3,66.2) 11.1/31.6 0.05 (0.02,0.07)
SNPs identified through Regression Trees
CHD (n=663, 180 incident events)
Conventional risk factors 0.652 0.077 0.686
Conventional risk factors & SNPs 0.686 0.124 0.709 41.5 (24.6,58.4) 21.5/20.0 0.04 (0.02,0.05)
Fatal or non-fatal MI or coronary intervention (n =768, 107incident events)
Conventional risk factors 0.679 0.050 0.694
Conventional risk factors & SNPs 0.704 0.077 0.718 42.9 (22.5,63.3) 14.0/28.9 0.03 (0.01,0.04)
*Conventional risk factors = Age, Sex, SBP, Total Cholesterol/HDL Cholesterol, Diabetes and/or glucose intolerance, Smoking.
Each analysis used only subjects without a diagnosis at baseline, as appropriate to investigate incident events, and with full genotypic data for included SNPs.
doi:10.1371/journal.pone.0057310.t003
Figure 1. ROC curves of prediction of coronary heart disease when GWAS significant SNPs were added to conventional risk factors.
A: ROC curves for CHD, comprised of fatal or non-fatal MI, angioplasty, coronary artery bypass surgery, angina and/or unspecified ischaemic heart
disease as a cause of death; B: ROC curves for diagnoses limited to fatal or non-fatal MI or coronary intervention (angioplasty or coronary artery
bypass surgery).
doi:10.1371/journal.pone.0057310.g001
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cohort, and found no improvement in discrimination or reclassifica-
tion. Additionally the investigators found that the genetic risk score
alone was not associated with risk of CVD; thismay be due to the use
of a broader phenotype. Davies et al. (2010) [33] assessed the
predictive utility for CHD and found a significant improvement in
the C-index when SNPs were added to conventional risk scores,
from 0.801 to 0.809, (P=0.0073). They additionally found that
weighting SNPs led to models that performed better than un-
weighted models. Ripatti et al. (2010) [34] also reported an
association between incident CHD and genetic risk score after
adjusting for conventional risk factors, however this was observed
through improvements in IDI and NRI, and did not lead to
significant changes in C-index. They also reported that though
family history was associated with increased risk of CVD,
adjustment for family history did not change the risk estimates of
the genetic risk score.
The use of a genetic risk score results in equal weighting of all
SNPs, possiblymissing relevant information on the relative effects of
eachSNPwithin themodel [32].Also, in the development of amodel
in which covariates are not unrelated, the ß coefficients need to be
adjusted to account for the impact covariates have on each other to
prevent distortion of the model. ROC curves measure discrimina-
tion but are ‘insensitive to change’ [19,35], however as our curves
showed, the changes in risk prediction did not always change
consistently over the full range of sensitivities, a large change in one
portion of the curvemay be clinically relevant but not represented in
summary measures. The clinical value was demonstrated by the
increased NRI, and subsequent increased odds of subjects with
CHD to have predicted risk$20%, showing that addition ofGWAS
SNPs can have clinical applicability.
There were a number of strengths and weaknesses of the current
study. A strength of the EAS population was the long follow-up of
15 years, and the prospective method that included regular contact
with study participants and general practitioners, as well as use of
hospital discharge records and death certificates. This enabled
confirmation of reported events, providing accurate phenotypic
data and minimising misclassification bias; as well as detailed and
accurate records for subjects that died during follow-up, thereby
removing survivor bias. Here we found that genetic data was more
informative than self-reported family history of CHD. This was
possibly due to the difficulty in collecting accurate reports of family
history in epidemiological studies, which would also exist clinically
and therefore not result in accurate risk prediction.
As the cohort was recruited from Edinburgh only and was
primarily white, the risk of population stratification was low.
However, the EAS study population was small for a genetic study.
There may also have been temporal trends that affected CHD risk
and consequently risk prediction, such as smoking habits and
primary prevention of CHD. At baseline, medications for CHD
risk factors were not as commonly used as recently, and during
follow-up a considerable portion of the population were prescribed
anti-hypertensive, lipid lowering, and/or diabetes treatments.
With such a long follow-up this may have been a confounder
that was not accounted for.
This is not a definitive list of predictive SNPs. Further analysis of
GWAS and fine mapping is necessary to identify causal SNPs that
will be more accurate in risk prediction. There remains the
possibility that some of the GWAS significant SNPs did not
contribute to risk prediction. It is also likely that there are gene-
environment and gene-gene interactions that were not accounted
for, for example Humphries et al. (2007) found an interaction with
smoking [32], and HMGCR genotypes may affect lipid lowering
responses to statins [36]. Though use of GWAS results removed
sources of bias associated with the inclusion of candidate gene
study results, there remain problems specifically associated with
GWAS, such as poor representation of low MAF SNPs, that
debatably have larger effect sizes [37]. However, we have shown
that use of a systematically selected panel of SNPs can significantly
improve prediction of CHD risk over-and-above conventional risk
factors, indicating that this approach to incorporating genotypic
data into prediction models has potential clinical utility.
Supporting Information
Figure S1 Density plots of risk scores in prediction of
CHD with addition of GWAS SNPs to conventional risk
factors. A: Plots for CHD, comprised of fatal or non-fatal MI,
angioplasty, coronary artery bypass surgery, angina and/or
unspecified ischaemic heart disease as a cause of death; B: Plots
for diagnoses limited to fatal or non-fatal MI or coronary
intervention (angioplasty or coronary artery bypass surgery). Solid
lines represent density curves of risk scores using conventional risk
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